Combined modalities approach for localized adult extremity soft-tissue sarcoma

Expert Review of Anticancer Therapy

Volumn 7, Issue 8, 2007, Pages 1135-1144

  Gronchi, Alessandro ^a   Olmi, Patrizia ^a   Casali, Paolo G ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Chemotherapy; Combined modalities; Isolated limb perfusion; Limb; Prognosis; Radiotherapy; Sarcoma; Surgery; Targeted therapy

Indexed keywords

ADENOVIRUS VECTOR; ALBUMIN; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; DACARBAZINE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; IMATINIB; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MELPHALAN; MESNA; TAXANE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN INHIBITOR;

ADJUVANT THERAPY; ADULT; ANGIOSARCOMA; BRACHYTHERAPY; CANCER CONTROL; CANCER LOCALIZATION; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; DERMATOFIBROSARCOMA PROTUBERANS; DRUG DOSE COMPARISON; EXTERNAL BEAM RADIOTHERAPY; HIGH RISK PATIENT; HUMAN; HYPERTHERMIA; LEIOMYOSARCOMA; LIMB PERFUSION; MONOTHERAPY; MORBIDITY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; REVIEW; SOFT TISSUE SARCOMA; SURGICAL TECHNIQUE; SYNOVIAL SARCOMA; TISSUE TRANSPLANTATION; TOURNIQUET; UNSPECIFIED SIDE EFFECT; VIRAL GENE THERAPY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARM; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; HUMANS; LEG; LIMB SALVAGE; PROGNOSIS; SARCOMA;

EID: 34548413977     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.7.8.1135     Document Type: Review

References (90)

1. Brennan M, Singer S, Maki RG. Soft tissue sarcoma In: Cancer. Principles and Practice of Oncology. DeVita VT, Hellmann S, Rosenberg SA (Eds). Lippincott Williams & Wilkins, PA, USA 1581-1637 (2005).
2. Greenlee RT, Hill-Harmon MB, Murray T et al. Cancer statistics, 2001. CA Cancer J. Clin. 51, 15-36, (2001).
3. Trojani M, Contesso G, Coindre JM et al. Soft tissue sarcomas of adults study of pathological prognostic variables and definition of a histopathologic grading system. Int. J. Cancer 33, 37-42 (1984).
4. Kattan MW, Leung D H Y, Brennan M F. Postoperative nomogram for 12-year sarcoma-specific death. J. Clin. Oncol. 20(3), 791-796 (2002).
5. Mariani L, Miceli R, Kattan MW et al. Validation and adaptation of a nomogram for predicting the survival of patients with extremity soft tissue sarcoma using a three-grade system. Cancer 103(2), 402-408 (2005).
6. Singer S, Corson K, Gonin JM et al. Prognostic factors predictive of survival and local recurrence for extemity soft tissue sarcoma. Ann. Surg. 219, 165-173 (1994).
7. Pisters PWT, Leung D H Y, Woodruff J et al. Analysis of prognostic factors in 1041 patients with localized soft tissue sarcoma of the extremities. J. Clin. Oncol. 14, 1679-1689 (1996).
8. Coindre JM, Terrier P, Bui NB et al. Prognostic factors in adult patients with locally controlled soft tisue sarcoma A study on 546 patients from the French Federation of Cancer Centers Sarcoma Group. J. Clin. Oncol. 14, 869-877 (1996).
9. Coindre JM, Terrier P, Guillou L et al. Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas. A study of 1240 patients from the French Federation of Canocer Centers Sarcoma Group. Cancer 91, 1914-1926, (2001).
10. Stojadinovic A, Leung D H Y, Allen P et al. Primary adult soft tissue sarcoma time-dependent influence of progostic variables. J. Clin. Oncol. 20, 4344-4352 (2002).
11. Weitz J, Antonescu CR, Brennan MF. Localized extremity soft tissue sarcoma improved knowledge with unchanged survival over time. J. Clin. Oncol. 21, 2719-2725 (2003).
12. Brennan MF. The enigma local recurrence. Ann. Surg. Oncol. 4, 1-12 (1997).
13. Lewis JJ, Leung D H Y, Casper ES et al. Multifactorial analysis of long-term folow-up (more than 5 years) of primary extremity sarcoma. Arch. Surg. 134, 190-194 (1999).
14. Gronchi A, Miceli R, Fiore M et al. Extremity soft tissue sarcoma adding to the prognostic meaning of local reccurence. Ann. Surg Oncol. 14(5), 1583-4590 (2007).
15. Trovik CS, Bauer HCF, Alvegard TA et al. Surgical margins, local recurrence and metastasis in soft tissue sarcomas 559 surgically-treated patients from the Scandinavian Sarcoma Group register. Eur. J. Cancer 36, 710-716 (2000).
16. Stojadinovic A, Leung DHY, Hoos A et al. Analysis of the prognostic significance of microscopic margins in 2084 localized primary adult soft tissue sarcomas. Ann. Surg 235, 424-433 (2002).
17. Zagars GK, Ballo MT, Pisters PWT et al. Prognostic factors for patients with localized soft tissue sarcoma treated with conservation surgery and radiation therapy. An analysis of 1225 patients. Cancer 97, 2530-2543 (2003).
18. Eilber FC, Rosen G, Nelson SD et al. High grade extremity soft tissue sarcomas Factor predictive of local recurrence and its effect on morbidity and mortality. Ann. Surg 237, 218-226 (2003).
19. Gronchi A, Casali PG, Mariani L et al. Status of surgical margins and prognosisin adult soft tissue sarcomas of the extremities. A series of 911 consecutive patients treated at a single institution. J. Clin. Oncol. 23(1), 96-104 (2005).
20. Stoeckle E, Gardet H, Coindre JM et al. Prospective evaluation of quality of surgery in soft tissue sarcoma. Eur. J. Surg Oncol. 32, 1242-1248 (2006).
21. Simon MA, Enneking WF. The management of soft tissue sarcoma of the extremities. J. Bone Joint Surg 58-A 317-327 (1976).
22. Rosenberg SA, Tepper J, Glatsein E et al. The treatment of soft tissue sarcoma of the extremities prospective randomized evaluation of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy. Ann. Surg 196, 305-315 (1982).
23. Yang JC, Chang AE, Baker AR et al. Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcoma of the extemity. J. Clin. Oncol. 16, 197-203 (1998).
24. Plsters PWT, Harrison LB, Leung DHY et al. Long-term results of a prospective randomized trial of adjuvant brachitherapy in soft tisue sarcoma. J. Clin. Oncol. 14, 859-868 (1996).
25. Grunhagen DJ, deWitt JHW, Graveland W et al. Outcome and prognostic factors analysis of 217 consecutive isolated limb perfusions with tumor necrosis factor-α and melphalan for limb threatening soft tissue sarcoma. Cancer 106(8), 1776-1784 (2006).
26. Pennacchioli E, Deraco M, Mariani L. et al. Advanced extremity soft tissue sarcoma: prognostic effect of isolated limb perfusion in a series of 88 patients treated at a single institution. Ann. Surg Oncol. 14(2), 553-559 (2007).
27. Plsters PWT, Patel SR, Prieto VG et al. Phase I trial of preoperative doxonibicine based concurrent chemoradiation and surgical resection for localized extremity and body wall soft tissue sarcoma. J. Clin. Oncol. 22(16), 3375-3380 (2004).
28. Meric F, Hess KR, Varma DGK et al. Radiographic response to neoadjuvant chemotherapy is a predictor of local control and survival in soft tissue sarcomas. Cancer 95, 1120-1126 (2002).
29. Kraybill WG, Henris J, Spiro IJ et al. Phase II study of neoadjuvant chemotherapy and radiation therapy in the management of high risk, high grade soft tissue sarcoma of the extremities and body wall: Radiation Therapy Oncology Group Trial 9514. J. Clin. Oncol. 24, 619-625 (2006).
30. Mack LA, Crowe PJ, Yang JL et al. Preoperative chemoradiotherapy (modified Eilber protocol) provide maximum local control and minimal morbidity in patients with soft tissue sarcoma. Ann. Surg Oncol. 12(8), 646-653 (2005).
31. Wunder JS, Nielsen TO, Maki RG et al. Opportunities for improving the therapeutic ratio for petients with sarcoma Lancet Oncol. 8(6), 513-524 (2007).
32. Bramwell VHC. Controversies surgical oncology: routine arythracydine based adjuvant chemotherapy for stage III extremity soft tissue sarcoma. Ann. Surg. Oncol. 14(4), 1254-1256 (2007).
33. Casali PG, Pioci P. Adjuvant chemotherapy for soft tissue sarcoma. Curr. Opin. Oncol. 17, 361-365 (2005).
34. Gutierrez JC, Perez EA, Moffat FL et al. should soft tissues sarcomas be treated at high-volume oentres? An analysis of 4205 patients. Ann. Surg 245(6), 952-958 (2007).
35. Kawaguchi N, Ahmed AR, Matsumoto S et al. The concept of curative margin in surgery for bone and soft tissue sarcoma. Clin Orthop. 419, 165-172 (2004).
36. Clarkson PW, Griffin AM, Catton CN et al. Epineural dissection is a ssfe technique that facilitateslimb salvage surgary. Clin. Orthop. Rel. Res 438, 92-96 (2005).
37. Lin PP, Diaz Pino E, Normand AN et al. Periosteal margin in soft tissue sarcoma. Cancer 109(3), 598-602 (2007).
38. Ferguson PC, Griffin AM, O'Sullivan B et al. Bone invasion in extremity soft tissue sarcoma. Cancer 106(12), 2692-2700 (2006).
39. Ghert MA, Davis AM, Griffin AM et al. The surgical and functional outcome of limb salvage surgery with vascular reconstruction for soft tissue sarcoma of the extremity. Ann. Surg Oncol. 12(12), 1102-1110 (2005).
40. Adelani MA, Holt GE, Dittus RS et al. Revascularization after segmental resection of low extremity soft tissue sarcoma. J. Surg. Oncol. 95, 455-460 (2007).
41. Ghert MA, Abudu A, Driver N et al. The indication for and the prognostic significance of amputation as the primary surgical procedure for localized soft tissue sarcoma of the extremity. Ann. Surg. Oncol. 12(1), 10-17 (2005).
42. Clark MA, Thomas JM. Amputation for soft tissue sarcoma. Lancet Oncol. 4, 335-342 (2003).
43. Suit HD, Spiro I. Role of radiation in the management of adult patients with sarcoma of soft tissue. Semin. Surg. Onco, 110, 347-356 (1994).
44. Barkley HT Jr, Martin RG, Romsdahl MM et al. Treatment of soft tissue sarcomas by preoperative irradiation and conservative surgical resection. Int. J. Radiat. Oncol. Biol. Phys 14, 693-699 (1988).
45. Wilson AN, Davis A, Bell RS et al. Local control of soft tissue sarcoma of the axtremity: thea experience of a multidisciplinary sarcoma group with definitive surgery and radiotherapy. Eur. J. Cancer 30A, 746-751 (1994).
46. Geer RJ, Woodruff JM, Casper ES et al. Management of small soft-tissues sarcoma of the extremity in adults. Arch. Surg 127, 1285-1289 (1992).
47. Rydholm A, Gustafson P, Rooser B et al. Limb-sparing surgery without radiotherapy based on anatomic location of soft tissue sarcoma. J. Clin. Oncol. 9, 1757-1765 (1991).
48. Karakousis CP, Proimakis C, Walsh DL. Primary soft tissue sarcoma of the extremities in adults. Br. J. Surg 82, 1208-1212 (1995).
49. Khanfir K, Alzieu L, Terrier P et al. Does adjuvant radiation therapy increase loco-regional control after optimal resection of soft tissue sarcoma of the extremities? Eur. J. Cancer 39, 1872-1880 (2003).
50. Baldini EH, Goldberg J, Jenner C et al. Long term outcomes after function-sparing surgery without radiotherapy for soft tissue sarcoma of thea extremities and trunk. J. Clin. Oncol. 17, 3252-3259, (1999).
51. Fabrizio PL, Stafford SL, Pritchard DJ. Extremity soft-tissue sarcomas selectively treated with surgery alone. Int. J. Radiat. Oncol. Biol. Phys 48, 227-232 (2000).
52. Pisters PWT, O'Sullivan B, Maki R: Evidence-based recommendations for local therapy for soft tissue sarcoma. J. Clin. Oncol. 25(8), 1003-1008 (2007).
53. Pitson G, Robinson P, Wilke D et al. Radiation response: an additional unique signature of myxoid liposarcoma. Int. J. Radiat. Oncol. Biol. Phys. 60(2),522-526 (2004).
54. O'Sullivan B, Davis AM, Turcotte R et al. Preoperative versus postoperative radiotherapy in soft tissue sarcoma of the limbs a randomized trial. Lancet 359, 2235-2241 (2002).
55. O'Sullivan B, Davis AM, Turcotte R et al. Five year results of a randomized Phase III trial of pre-operative vs post-operative radiotherapy in extremity soft tissue sarcoma. J. Clin. Oncol. 22, 815 (2004). (Abstract 9007).
56. Davis AM, O'Sullivan B, Turcotte R et al. Late radiation morbidity following randomization to preoperative versus postoperative radiotherapy in extremity soft tissue sarcoma. Radiother. Oncol. 75(1), 48-53 (2005).
57. Wolfson AH. Preoperative vs postoperative radiation therapy for extremity soft tissue sarcoma controversy and present management. Curr. Opin. Oncol. 17, 357-360 (2005).
58. Pisters PWT, Ballo MT, Patel SR. Preoperative chemoradiation treatment strategies for localized sarcoma. Ann. Surg. Oncol. 9(6), 535-542 (2002).
59. Lláoer C, Delannes M, Minsat M et al. Low-dose intraoperative brachytherapy in soft tissue sarcomas involving neurovascular structure. Radiother. Oncol. 78(1), 10-16 (2006).
60. Alektiar KM, Hong L, Brennan MF et al. Intensity modulated radiation therapy for primary soft tissue sarcoma of the extremity: preliminary results. Int. J. Radiat. Oncol. Biol. Phys 68(2), 458-464 (2007).
61. Brada M, Pijls-Johannesma M, De Ruysscher D. Proton therapy in clinical practice current clinical evidence. J. Clin. Oncol. 25(8), 965-969 (2007).
62. Eggermont AMM, Koops H, Klausner JM et al. Isolated limb perfusion with tumor neorosis factor and melphalan for limb salvage in 186 patients locally advanced soft tissue extremity sarcoma: the cumulative multicenter European experience. Ann. Surg. 224, 756-764 (1996).
63. Bonvalot S, Laplanche A, Lejune F et al. Limb salvage with isolated perfusion for soft tissue sarcoma could less TNF-α be better? Ann. Oncol. 16, 1061-1068 (2005).
64. Di Filippo F, Garinei R, Anzà M et al. Doxorubicin in isolation limb perfusion in the treatment of advanced limb soft tissue sarcoma. J. Exp. Clin. Cancer Res 22(Suppl. 4), 81-87 (2003).
65. Hannay J, Davis JJ, Yu D et al. Isolated limb perfusion: a novel delivery system for wild-type p53 and fiber-modified oncolytic adenoviruses to extremity sarcoma. Gene Ther. 14(8), 671-681 (2007).
66. Thijseens KM, Hoekstra-Weebers JE, van Ginkel RJ. Quality of life after hyperthermic isolated limb perfusion for locally advanced extremity soft tissue Sarcoma. Ann. Surg. Oncol. 13(6), 864-871 (2006).
67. Sarcoma Meta-Analysis Collaboration. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma data. Lancet 350, 1647-1654 (1997).
68. Frustaci S, Gherlinzoni F, De Paoli A et al. Adjuvent chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. J. Clin. Oncol. 19, 1238-1247 (2001).
69. Woll PJ, Van Glabbeke M, Hohenberger P et al. Adjuvant chemotherapy with doxorubicine and ifosfamide in resected soft tissue sarcoma: interim analysis of a Phase III trial. J. Clin. Oncol. 25(18s), 547 (2007) (Abstract 10008).
70. Patel SR, Vadhan-Raj S, Papadopolous N et al. High-dose ifosfamide in bone and soft tissue sarcomas results of Phase II and pilot studies - dose-response and schedule dependence. J. Clin. Oncol. 15(6), 2378-2384 (1997).
71. Cormier JN, Huang X, Xing Y et al. Cohort analysis of patients with localized, high-risk, extremity soft tissue sarcoma treated at two cancer centers: chemotherapy-associated outcomes. J. Clin. Oncol. 22, 4567-4574
72. Eilber FC, Eilber FR, Eckardt J et al. The impact of chemotherapy on the survival of patients with high-grade primary extremity liposarcoma. Ann. Surg. 240, 686-695 (2004).
73. Ferrari A, Gronchi A, Casanova M et al. Synovial sarcoma: a retrospective analysis of 271 patients of all ages treated at a single institution. Cancer 101, 627-634 (2004).
74. Grobmyer SR, Maki RG, Demetri GD et al. Neo-adjuvant chemotherapy for primary high-grade extremity soft tissue sarcoma. Ann. Oncol. 15, 1667-1672 (2004).
75. Gortzak E, Azzarelli A, Buesa J et al. A randomised Phase II study on neo-adjuvant chemotherapy for 'high-risk' adult soft-tissue sarcoma. Eur. J. Cancer 37(9), 1096-1103 (2001).
76. Edmonson JH, Petersen IA, Shives TC et al. Chemotherapy, irradiation, and surgery for function-preserving therapy of primary extremity soft tissue sarcomas: initial treatment with ifosfamide, mitomycin, doxorubicin, and cisplatin plus granulocyte macrophage-colony-stimulating factor. Cancer 94(3), 786-792 (2002).
77. Eilber FC, Rosen G, Eckardt J et al. Treatment-induced pathologic necrosis: a predictor of local recurrence and survival in patients receiving neoadjuvant therapy for high grade extremity soft tissue sarcoma. J. Clin. Oncol. 19, 3203-3209 (2001).
78. Iseels RD, Lindner LH, Wust P et al. Regional hyperthermia improves response and survival when combined with systemic chemotherapy in the management of locally advanced, high grade soft tissue sarcoma of the extremities, the body wall, and the abdomen: a Phase III randomized pros. J. Clin. Oncol. 25(18S), 547S (2007) (Abstract 10009).
79. Groseo F, Jones RL, Demetri GD et al. Efficacy of trabectidine (ET 743) in advanced pre-treated myxoid liposarcoma. Lancet Oncol. 8(7), 595-602 (2007).
80. Morgan JA, Le Cesne A, Chawla S et al. Randomized Phase II study of trabectidine in patients with liposarcoma and leiomyosarcoma after failure of prior anthracycline and ifosfamide. J. Clin. Oncol. 25, 18S(2007) (Abstract 10060).
81. Dileo P, Grosso F, Casanova M et al. Trabectidine in metastatic Ewing's family tumors patients progressing after standard chemotherapy. J. Clin. Oncol. 25, 18S (2007) (Abstract 10040).
82. Hensley ML, Maki R, Venkatraman E et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma:results of a Phase II trial. J. Clin. Oncol. 20, 2824-2831 (2002).
83. Leu KM, Ostruszka LJ, Shewach D et al. Laboratory and clinical evidence of synergistic cytotoxicity of sequential treament with gemcitabine followed by docetaxel in the treatment of sarcoma. J. Clin. Oncol. 22(9), 1706-1712 (2004).
84. Maki R, Hensley ML, Wathen JK et al. A SARC multicenter Phase III study of gemcitabine vs gemcitabine and docetaxel in patients with metastatic soft tissue sarcoma. J. Clin. Oncol. 24, 18S (2006) (Abstract 9514).
85. Fata F, O'Reilly E, Ilson D et al. Raditaxel in the treatment of patients with angiosarcoma of the scalp or face. Cancer 86(10), 2034-2037 (1999).
86. Penel N, Bui B, Bay JO et al. Weekly paclitaxel in metastatic angiosarcoma. A FNCLCC french sarcoma group (GSF-GETO) Phase II trial. J. Clin. Oncol. 25, 18S(2007) (Abstract 10002).
87. Leahy M, Ray-Coquard I, Verweij J et al. Brostallicin, an agent with potential activity in metastatic soft tissue sarcoma: a Phase II study from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Eur. J. Cancer 43(2), 308-315 (2007).
88. McArthur GA, Demetri GD, van Oosterom A et al. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225. J. Clin. Oncol. 23(4), 866-873 (2005).
89. D'Adamo DR, Keohan M, Schuetze S et al. Clincal results of a Phase II study of sorafenib in patients with non GIST sarcomas (CTEP study 7060). J. Clin. Oncol. 25, 18S(2005) (Abstract 10001).
90. Chawla SP, Tolcher AW, Staddon AP et al. Survival results with AP23573, a novel mTOR inhibitor, in patients with advanced soft tissue or bone sarcomas: update of a Phase II trial. J. Clin. Oncol. 25, 18s(2007) (Abstract 10076).